T1	p 205 245	patients with atrial fibrillation ( AF )
T2	p 715 852	patients with nonvalvular AF and at least 1 risk factor for stroke . Recruitment concluded with a total of 18,113 patients . Patients who
T3	i 63 105	long-term anticoagulant therapy , warfarin
T4	i 122 165	dabigatran . Vitamin K antagonists ( VKAs )
T5	i 478 486	warfarin
T6	o 982 1103	systemic embolism . Safety outcomes are bleeding , liver function abnormalities , and other adverse events . Adjudication